Looking for our Business Solutions? Click here:CloudQuote APIsContact Us

Nuvalent, Inc. - Class A Common Stock (NUVL)

94.77
-2.29 (-2.36%)
NASDAQ · Last Trade: Mar 22nd, 7:40 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close97.06
Open97.06
Bid38.33
Ask115.00
Day's Range94.43 - 98.70
52 Week Range55.54 - 113.01
Volume951,897
Market Cap296.57M
PE Ratio (TTM)-16.20
EPS (TTM)-5.9
Dividend & YieldN/A (N/A)
1 Month Average Volume539,679

Chart

About Nuvalent, Inc. - Class A Common Stock (NUVL)

Nuvalent Inc is a biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company specializes in creating innovative drug candidates that aim to effectively treat specific types of tumors by addressing the underlying genetic mechanisms driving disease progression. By leveraging advanced science and technology, Nuvalent strives to improve treatment options and outcomes for patients with difficult-to-treat cancers, emphasizing precision medicine to enhance the efficacy and safety of oncology treatments. Read More

News & Press Releases

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rallyfool.com
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
Via The Motley Fool · March 16, 2026
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decisionfool.com
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Via The Motley Fool · March 13, 2026
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drugfool.com
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Via The Motley Fool · March 13, 2026
Why Did Nuvalent Stock Surge 15% Today?stocktwits.com
Via Stocktwits · November 17, 2025
Earnings Scheduled For October 30, 2025benzinga.com
Via Benzinga · October 30, 2025
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipelinefool.com
Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Via The Motley Fool · March 13, 2026
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%fool.com
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Via The Motley Fool · February 23, 2026
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Datafool.com
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via The Motley Fool · February 19, 2026
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Aheadfool.com
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
Via The Motley Fool · February 19, 2026
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transitionfool.com
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
Via The Motley Fool · February 19, 2026
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Salefool.com
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
Via The Motley Fool · February 19, 2026
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Providerfool.com
BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
Via The Motley Fool · February 19, 2026
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally stabilizing and corporate balance sheets bulging with record-breaking liquidity, the stage is set for a massive wave of
Via MarketMinute · December 30, 2025
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?fool.com
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via The Motley Fool · December 3, 2025
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Awayfool.com
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via The Motley Fool · December 3, 2025
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investorsfool.com
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Via The Motley Fool · December 3, 2025
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Sharesfool.com
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?
Via The Motley Fool · December 3, 2025
Biotech Stock Gets Booted in Latest Fund Updatefool.com
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via The Motley Fool · November 19, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · November 17, 2025
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancerbenzinga.com
Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.
Via Benzinga · November 17, 2025
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · November 17, 2025
Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancerinvestors.com
Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental drug.
Via Investor's Business Daily · November 17, 2025
Wondering what's happening in today's after-hours session?chartmill.com
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · November 14, 2025
This Waste Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Via Benzinga · November 12, 2025
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · August 19, 2025